Clinical trial • Phase I/II • Oncology
Avelumab for Gestational trophoblastic neoplasia (low-risk)
Phase I/II trial of Avelumab for Gestational trophoblastic neoplasia (low-risk). None/Not specified-controlled. 26 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Gestational trophoblastic neoplasia (low-risk)
- Trial Stage
- Phase I/II
- Drug Modality
- Monoclonal antibody | Small molecule
Key dates
- Initial CTIS Submission Date
- 05-07-2024
- First CTIS Authorization Date
- 06-08-2024
Trial design
None/Not specified-controlled Phase I/II trial across 9 sites in France.
- Comparator
- None/Not specified
- Target Sample Size
- 26
Recruitment
- Planned Sample Size
- 26
- Recruitment Window Months
- 37
Geography
- Total Number Of Sites
- 9
- Total Number Of Participants
- 26
France
- Earliest CTIS Part Ii Submission Date
- 12-07-2024
- Latest Decision Or Authorization Date
- 31-01-2025
- Processing Time Days
- 203
- Number Of Sites
- 9
- Number Of Participants
- 26
Sites
- Site Name
- Hospices Civils De Lyon
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Benoit You
- Principal Investigator Email
- benoit.you@chu-lyon.fr
- Contact Person Name
- Benoit You
- Contact Person Email
- benoit.you@chu-lyon.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Jean-Pierre LOTZ
- Principal Investigator Email
- jean-pierre.lotz@tnn.aphp.fr
- Contact Person Name
- Jean-Pierre LOTZ
- Contact Person Email
- jean-pierre.lotz@tnn.aphp.fr
- Site Name
- Centre de Coordination en Cancérologie François Baclesse
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Florence JOLY
- Principal Investigator Email
- f.joly@baclesse.unicancer.fr
- Contact Person Name
- Florence JOLY
- Contact Person Email
- f.joly@baclesse.unicancer.fr
- Site Name
- Institut Bergonie
- Department Name
- ONCOLOGIE MEDICALE
- Principal Investigator Name
- Coriolan LEBRETON
- Principal Investigator Email
- c.lebretont@bordeaux.unicancer.fr
- Contact Person Name
- Coriolan LEBRETON
- Contact Person Email
- c.lebretont@bordeaux.unicancer.fr
- Site Name
- Institut Paoli Calmettes
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Magali PROVANSAL
- Principal Investigator Email
- provansalm@ipc.unicancer.fr
- Contact Person Name
- Magali PROVANSAL
- Contact Person Email
- provansalm@ipc.unicancer.fr
- Site Name
- Centre Antoine Lacassagne
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Philippe FOLLANA
- Principal Investigator Email
- PHILIPPE.FOLLANA@NICE.UNICANCER.FR
- Contact Person Name
- Philippe FOLLANA
- Contact Person Email
- PHILIPPE.FOLLANA@NICE.UNICANCER.FR
- Site Name
- Oncopole Claudius Regaud
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Laurence GLADIEFF
- Principal Investigator Email
- gladieff.laurence@iuct-oncopole.fr
- Contact Person Name
- Laurence GLADIEFF
- Contact Person Email
- gladieff.laurence@iuct-oncopole.fr
- Site Name
- Centre De Lutte Contre Le Cancer Eugene Marquis
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Thibault DE LA MOTTE ROUGE
- Principal Investigator Email
- t.delamotterouge@rennes.unicancer.fr
- Contact Person Name
- Thibault DE LA MOTTE ROUGE
- Contact Person Email
- t.delamotterouge@rennes.unicancer.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Oncologie médicale
- Principal Investigator Name
- Benoit You
- Principal Investigator Email
- benoit.you@chu-lyon.fr
- Contact Person Name
- Benoit You
- Contact Person Email
- benoit.you@chu-lyon.fr
Sponsor
Primary sponsor
- Full Name
- Hospices Civils De Lyon
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Avelumab
- Active Substance
- Avelumab
- Modality
- Monoclonal antibody
- Investigational Product Name
- Methotrexate
- Active Substance
- Methotrexate
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)